Infinity Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 83   

Articles published

INFI 1.20 +0.01 (0.84%)
price chart
Why Infinity Pharmaceuticals Inc. Is Being Obliterated Today
So what: Infinity Pharmaceuticals released data from its phase 2 monotherapy study of duvelisib, the company's investigational compound being researched as a possible treatment for non-Hodgkin lymphoma.
Why Infinity Pharmaceuticals Crashed  24/7 Wall St.
Infinity Pharmaceuticals' Disappointing Data  Barron's
Will Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) beat earning estimates again?
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) is projected to declare fiscal fourth quarter financial results right after the stock market's official close on February 28, 2017.
Analysts Reviewing Stock: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)  Street Updates
Infinity Pharma cuts 100 jobs after AbbVie deal is terminated
Infinity Pharmaceuticals Inc. said Tuesday it will cut 100 jobs and give retention bonuses to remaining employees - including a total of almost $1 million to four top executives - in a bid to continue developing its experimental treatment for blood ...
AbbVie (ABBV) Exercises Right to End Duvelisib Collaboration with Infinity ...  StreetInsider.com
AbbVie scraps Infinity collab in wake of weak data; biotech slashes jobs  FierceBiotech
Infinity Pharmaceuticals stock plunges toward record low after drug study ...
Shares of Infinity Pharmaceuticals Inc. INFI, +0.84% plummeted 66% in premarket trade Tuesday, toward an all-time low, after the biotechnology company announced a restructuring that would reduce its workforce by 21% in the wake of disappointing ...
Biotech Stocks To Put On Your Watch List: Infinity Pharmaceuticals, Inc ...
Shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) added 1.75% by the end of trading session at $1.16. The net percentage change is -86.34% over the last 12 months.
Upcoming Earnings Report: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) gained 0.82% to reach at the trading price of $1.23 as it is set to release its next quarterly earnings report on February 28, 2017.
The Infinity Pharmaceuticals Inc. (INFI) Receives $1.55 Average Price Target ...  DailyQuint
Next Weeks Broker Price Targets For Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)  Fiscal Standard
Infinity Pharmaceuticals Inc. (INFI) Rating Reiterated by JPMorgan Chase & Co.
Infinity Pharmaceuticals Inc. (NASDAQ:INFI)'s stock had its “hold” rating reissued by JPMorgan Chase & Co. in a research report issued to clients and investors on Thursday.
FY2016 Earnings Estimate for Infinity Pharmaceuticals Inc. Issued By William ...  BBNS
Infinity Pharmaceuticals Stock Could Reach $15
Infinity's newest pipeline candidate is an immuno-oncology product in Phase 1 studies, IPI-549, is an oral selective PI3K-gamma inhibitor that targets the tumor microenvironment for solid tumors.
Brokerage Firm Target Review on Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)
Equity research analysts have provided views on where they believe Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) will be trading in the future.
Trade: The FBR & Co Analysts Increase Earnings Estimates for Infinity ...  DailyQuint
Stock Perspective: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Company ...  CSZ News
Analysts Set Infinity Pharmaceuticals Inc. (INFI) Target Price at $1.50
Infinity Pharmaceuticals logo Infinity Pharmaceuticals Inc. (NASDAQ:INFI) has been given an average rating of “Hold” by the ten ratings firms that are covering the firm.
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Reviewed By Analysts  The De Soto Edge